Wall Street analysts forecast that Danaher Co. (NYSE:DHR) will announce earnings of $0.93 per share for the current quarter, according to Zacks. Eight analysts have issued estimates for Danaher’s earnings. The highest EPS estimate is $0.94 and the lowest is $0.91. Danaher reported earnings of $0.85 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 9.4%. The firm is scheduled to report its next quarterly earnings results on Thursday, April 19th.
On average, analysts expect that Danaher will report full year earnings of $4.37 per share for the current year, with EPS estimates ranging from $4.30 to $4.50. For the next financial year, analysts expect that the business will post earnings of $4.75 per share, with EPS estimates ranging from $4.64 to $4.91. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Danaher.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.03. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The business’s revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $1.05 earnings per share.
A number of research analysts have weighed in on DHR shares. Stifel Nicolaus raised their price target on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Cowen restated a “buy” rating and issued a $110.00 price target on shares of Danaher in a research note on Tuesday, January 30th. UBS Group started coverage on Danaher in a research note on Monday, January 22nd. They issued a “buy” rating and a $99.97 price target for the company. Robert W. Baird restated a “buy” rating on shares of Danaher in a research note on Friday, January 12th. Finally, Citigroup raised their price target on Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $100.68.
Danaher (NYSE DHR) traded up $1.97 during mid-day trading on Wednesday, reaching $99.33. The company’s stock had a trading volume of 1,646,735 shares, compared to its average volume of 2,780,000. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market capitalization of $69,290.00, a P/E ratio of 28.38, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04. Danaher has a 12-month low of $78.97 and a 12-month high of $104.82.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Thursday, March 29th will be paid a dividend of $0.16 per share. This is an increase from Danaher’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Wednesday, March 28th. Danaher’s payout ratio is currently 16.00%.
In related news, insider Rainer Blair sold 51,080 shares of Danaher stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $97.26, for a total transaction of $4,968,040.80. Following the completion of the sale, the insider now directly owns 50,477 shares of the company’s stock, valued at approximately $4,909,393.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of Danaher stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now directly owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders have sold a total of 288,123 shares of company stock valued at $29,162,927 over the last quarter. 12.20% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. GQG Partners LLC acquired a new stake in Danaher during the 2nd quarter worth approximately $101,000. Zions Bancorporation lifted its holdings in Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares during the last quarter. Patten Group Inc. lifted its holdings in Danaher by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares during the last quarter. First Personal Financial Services lifted its holdings in Danaher by 128.9% during the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 691 shares during the last quarter. Finally, Calton & Associates Inc. acquired a new stake in Danaher during the 4th quarter worth approximately $114,000. 77.05% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://ledgergazette.com/2018/02/24/zacks-brokerages-anticipate-danaher-co-dhr-will-post-earnings-of-0-93-per-share.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.